In an effort to expand its global reach, Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced plans on January 31, 2025, to upgrade its Intelligent Fingerprinting Drug Screening System with multilingual capabilities. This enhancement aims to cater to over 4 billion users worldwide and support the Company’s strategic expansion goals.
The upgrade will enable the Drug Screening System to support multiple languages spoken across North and South America, Europe, Asia Pacific, and the Middle East. By introducing these multilingual features, INBS seeks to make its system accessible to a diverse customer base and address the needs of organizations operating in multilingual environments.
Harry Simeonidis, President & CEO of Intelligent Bio Solutions, emphasized the significance of the upgrade, stating, “As we expand our global footprint, it is essential that our solutions are accessible and adaptable to meet the needs of an increasingly diverse customer base.” He further highlighted that the multilingual update will pave the way for entering new international markets and customer segments, thereby supporting revenue growth.
INBS’ Intelligent Fingerprinting Drug Testing Solution utilizes innovative fingerprint sweat analysis to detect multiple substances of abuse concurrently. The addition of multilingual capabilities aligns with the Company’s plans to enhance its presence in key markets worldwide, including its anticipated entry into the US market in 2025.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. is a medical technology company that specializes in delivering rapid, non-invasive testing solutions. The Company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis to detect the recent use of various drugs. Find more information at http://www.ibs.inc/.
The upgrade to the Drug Screening System signifies an important advancement in INBS’ mission to provide accessible testing solutions on a global scale. While forward-looking statements within the release highlight projections and goals, Intelligent Bio Solutions Inc. continues to drive innovation in the medical technology sector.
Please note that the information disclosed in the Form 8-K filing and subsequent Press Release is being provided as a disclosure and is not filed for the purpose of the Securities Exchange Act of 1934. The Company’s ability to realize the benefits of this upgrade may be impacted by unforeseen circumstances or factors.
For further information, please refer to the Company’s official website or contact Intelligent Bio Solutions Inc. directly.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GBS’s 8K filing here.
About GBS
GBS Inc operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.
